Abbott Japan And Eisai Receive Approval To Market The Pancreatic Digestive Enzyme Replacement Drug Lipacreon(R) (pancrelipase) In Japan
Links shared publicly online about this topic.
- 337total visits
Abbott Japan And Eisai Receive Approval To Market The Pancreatic Digestive Enzyme Replacement Drug Lipacreon(R) (pancrelipase) In Japan
Abbott Japan Co., Ltd. and Eisai Co., Ltd. (TSE: 4523) announced today that they have received approval to market the pancreatic enzyme replacement drug Lipacreon(R)(pancrelipase) in Japan as a pa
View full resource at medicalnewstoday.com
Tags: Digestion, Pancreatic Disease, Drug, Eisai
Most Recently Shared on April 26, 2011 at 12:05 pm By:
Abbott Japan And Eisai Receive Approval To Market The Pancreatic Digestive Enzyme Replacement Drug Lipacreon(R) (pancr... http://mnt.to/3V2Y
Also Shared By:
Advertisement
MNT Cystic Fibrosis
@mnt_cysticfibro
Abbott Japan And Eisai Receive Approval To Market The Pancreatic Digestive Enzyme Replacement Drug Lipacreon(R) (pancr... http://mnt.to/3V2Y
1 year ago...